Multidimensional Strategies in Oncology: From Macrocyclic Kinase Inhibitors to Physicochemical and Transcriptomic Diagnostics.
Three recent inventions highlight complementary advances in oncology: macrocyclic multitarget ALK inhibitors for resistant NSCLC, impedance-based cfDNA staging as a label-free diagnostic, and transcri
APA
Renner AC, Kargbo RB (2026). Multidimensional Strategies in Oncology: From Macrocyclic Kinase Inhibitors to Physicochemical and Transcriptomic Diagnostics.. ACS medicinal chemistry letters, 17(1), 69-71. https://doi.org/10.1021/acsmedchemlett.5c00715
MLA
Renner AC, et al.. "Multidimensional Strategies in Oncology: From Macrocyclic Kinase Inhibitors to Physicochemical and Transcriptomic Diagnostics.." ACS medicinal chemistry letters, vol. 17, no. 1, 2026, pp. 69-71.
PMID
41531945
Abstract
Three recent inventions highlight complementary advances in oncology: macrocyclic multitarget ALK inhibitors for resistant NSCLC, impedance-based cfDNA staging as a label-free diagnostic, and transcriptome-driven prediction of KRAS inhibitor response. Together, they illustrate an emerging paradigm in precision oncology that integrates molecular design, biophysical classification, and computational phenotyping to refine therapeutic selection and improve clinical outcomes.